Publicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (16)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

  2. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

    American Journal of Hematology

2023

  1. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  2. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

  3. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

  4. Spanish registry of thrombotic thrombocytopenic purpura (REPTT): Data evidence and new developments

    Transfusion and Apheresis Science, Vol. 62, Núm. 3

2022

  1. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC

    Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10

  2. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

    Blood Advances, Vol. 6, Núm. 24, pp. 6219-6227

2021

  1. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

2020

  1. Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 4, pp. 651-658

2018

  1. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

    Blood Advances, Vol. 2, Núm. 14, pp. 1719-1737

  2. Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes

    European Journal of Haematology, Vol. 101, Núm. 3, pp. 332-339

2015

  1. Achievement of early complete donor chimerism in CD25+-activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation

    Experimental Hematology, Vol. 43, Núm. 1, pp. 4-13

  2. Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis

    Annals of Hematology, Vol. 94, Núm. 6, pp. 947-954

  3. The genotype of the donor for the (GT)n polymorphism in the promoter/enhancer of FOXP3 Is associated with the development of severe acute GVHD but does not affect the GVL effect after myeloablative HLA-Identical allogeneic stem cell transplantation

    PLoS ONE, Vol. 10, Núm. 10

2013

  1. Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does -7/7q- detection by FISH have prognostic value?

    Leukemia Research, Vol. 37, Núm. 4, pp. 416-421